tradingkey.logo
tradingkey.logo
Search

Orca Bio Announces FDA Review Extension Of BLA For Orca-T For The Treatment Of Hematologic Malignancies

ReutersApr 1, 2026 12:26 PM

-

  • ORCA BIO ANNOUNCES FDA REVIEW EXTENSION OF BLA FOR ORCA-T FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

  • ORCA BIO: NEW PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS JULY 6, 2026

Further company coverage: [ ]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI